The increasing availability and heightened sensitivity of PSMA PET/CT in determining an accurate evaluation of treatment response in prostate cancer clinical development proves difficult and complex for study designs and blinded independent central read.
Oliver Bohnsack, MD PhD MBA
Vice President, Medical Imaging and Head of Oncology, Calyx
In leading the imaging component of oncology studies for Calyx’s global customers, Oliver leverages his experience from supporting over 600 clinical trials – with various indications, complexities, and in all phases of development – which led to the approval of over 20 oncology treatments. He is co-author of the immune-related response criteria (irRC, 2009), first author of irRECIST (2014), and co-author of Comparison of Assessments using RECIST and irRECIST by Eggleton P. et al. (2020).